., the world’s leading developer and manufacturer of retinal prostheses, today announced that a U.S. Food and Drug Administration (FDA) Ophthalmic Devices Advisory Panel has been scheduled to review ...
SYLMAR, Calif.--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are ...
SYLMAR, Calif.--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are ...
CPT copyright 2013 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. CMS has approved Second Sight ...
Shares of Second Sight Medical Products Inc. soared 104.2% on heavy volume in midday trading Monday, bringing its two-day gain to 728.7%, after the Food and Drug Administration approved the company's ...
Second Sight Medical Products shares trade more than 400% higher after the company reported that the FDA granted approval for its Argus 2s Retinal Prosthesis System designed to deliver useful ...
The Argus II Retinal Prosthesis System is the result of more than 20 years of research and development to restore some functional vision to patients with severe vision loss. Duke is one of 13 sites ...
Second Sight Medical Products, Inc. Receives FDA Approval for the Argus 2s Retinal Prosthesis System
LOS ANGELES--(BUSINESS WIRE)-- Second Sight Medical Products (NASDAQ:EYES) a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful ...
The Argus II, a “bionic eye”, is intended to provide electrical stimulation of the retina to elicit visual perception in blind subjects with severe to profound retinitis pigmentosa, according to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results